Traduction de «autorisation complète » (Français → Anglais) :

full authorization

Modifiers The following fourth-character subdivisions are for use with categories O03-O06: Incomplete abortion includes retained products of conception following abortion. Code Title .0 Incomplete, complicated by genital tract and pelvic infection With conditions in O08.0 .1 Incomplete, complicated by delayed or excessive haemorrhage With conditions in O08.1 .2 Incomplete, complicated by embolism With conditions in O08.2 .3 Incomplete, with other and unspecified complications With conditions in O08.3-O08.9 .4 Incomplete, without compl ...[+++]ication .5 Complete or unspecified, complicated by genital tract and pelvic infection With conditions in O08.0 .6 Complete or unspecified, complicated by delayed or excessive haemorrhage With conditions in O08.1 .7 Complete or unspecified, complicated by embolism With conditions in O08.2 .8 Complete or unspecified, with other and unspecified complications With conditions in O08.3-O08.9 .9 Complete or unspecified, without complication | With conditions in O08.0 | With conditions in O08.1 | With conditions in O08.2 | With conditions in O08.3-O08.9 | With conditions in O08.0 | With conditions in O08.1 | With conditions in O08.2 | With conditions in O08.3-O08.9

gross vehicle weight rating | GVWR | GVW | rated gross vehicle weight

Any instance of care ordered by or provided by someone impersonating a physician, nurse, pharmacist, or other licensed healthcare provider

gross vehicle mass | gross vehicle weight | gross vehicle weight rating | maximum authorised mass | permissible maximum weight | GVM [Abbr.] | GVW [Abbr.] | GVWR [Abbr.] | MAM [Abbr.]

absorption costing | full absorption costing | full cost accounting | full costing | allocation costing

Definition: This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth character codes are applicable to all substances. Identification of the psychoactive substance should be based on as many sources of information as possible. These include self-report data, analysis of blood and other body fluids, characteristic physical and psychological symptom ...[+++]s, clinical signs and behaviour, and other evidence such as a drug being in the patient's possession or reports from informed third parties. Many drug users take more than one type of psychoactive substance. The main diagnosis should be classified, whenever possible, according to the substance or class of substances that has caused or contributed most to the presenting clinical syndrome. Other diagnoses should be coded when other psychoactive substances have been taken in intoxicating amounts (common fourth character .0) or to the extent of causing harm (common fourth character .1), dependence (common fourth character .2) or other disorders (common fourth character .3-.9). Only in cases in which patterns of psychoactive substance-taking are chaotic and indiscriminate, or in which the contributions of different psychoactive substances are inextricably mixed, should the diagnosis of disorders resulting from multiple drug use (F19.-) be used. | Modifiers The following fourth-character subdivisions are for use with categories F10-F19: Code Title .0 Acute intoxication A condition that follows the administration of a psychoactive substance resulting in disturbances in level of consciousness, cognition, perception, affect or behaviour, o ...

Definition: A disorder characterized by a partial or complete loss of the normal integration between memories of the past, awareness of identity and immediate sensations, and control of bodily movements (see F44.-), but arising as a consequence of an organic disorder.

In the case of certain categories of medicinal products, however, in order to meet unmet medical needs of patients and in the interests of public health, it may be necessary to grant marketing authorisations on the basis of less complete data than is normally the case and subject to specific obligations, hereinafter ‘conditional marketing authorisations’.

In contrast, it will normally never be possible to assemble a full dossier in respect of a marketing authorisation granted in exceptional circumstances.

Where conditional marketing authorisations are granted, they should be restricted to situations where only the clinical part of the application dossier is less complete than normal.

Although the data upon which an opinion on a conditional marketing authorisation is based may be less complete, the risk-benefit balance, as defined in Article 1(28a) of Directive 2001/83/EC should be positive.